Analysis of different DNA vaccines for protection of experimental influenza A virus infection

Viral Immunology

Volumn 24, Issue 4, 2011, Pages 321-330

  Wiesener, Nadine ^a   Schütze, Tatjana ^a   Lapp, Sara ^a   Lehmann, Melissa ^a   Jarasch Althof, Nadine ^a   Wutzler, Peter ^a   Henke, Andreas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; MIXED DNA VACCINE; PARIETAL CELL ANTIBODY; PLASMID VECTOR; PVIVO; PVIVO HEMAGGLUTININ MATRIX NEURAMINIDASE; PVIVO HEMAGGLUTININ MATRIX PROTEIN 2; PVIVO MATRIX PROTEIN 1; PVIVO MATRIX PROTEIN 2; PVIVO NONSTRUCTURAL PROTEIN 1; PVIVO NONSTRUCTURAL PROTEIN 1 NONSTRUCTURAL PROTEIN 2; PVIVO NONSTRUCTURAL PROTEIN 2; PVIVO NUCLEOPROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOPATHOLOGY; INFLUENZA A; INFLUENZA VIRUS A; LD 50; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PLASMID; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS; RODENT DISEASES; SURVIVAL ANALYSIS; VACCINES, DNA; VIRAL PROTEINS;

ANIMALIA; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 80051752020     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0001     Document Type: Article

References (46)

1. Bot A, Antohi S, Bot S, Garcia-Sastre A, and Bona C: Induction of humoral and cellular immunity against influenza virus by immunization of newborn mice with a plasmid bearing a hemagglutinin gene. Int Immunol 1997;9:1641-1650. (Pubitemid 27494127)
2. Chen J, Fang F, Li X, Chang H, and Chen Z: Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 2005;23:4322-4328. (Pubitemid 40991237)
3. Chen Q, Kuang H, Wang H, et al.: Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 2009;38:30-38.
4. Chen RT: Vaccine risks: real, perceived and unknown. Vaccine 1999;17(Suppl 3):S41-S46. (Pubitemid 29516679)
5. Chen W, Calvo, PA, Malide D, et al.: A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001;7:1306-1312. (Pubitemid 34007934)
6. Chen Z, Matsuo K, Asanuma H, et al.: Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 1999;17:653-659. (Pubitemid 29074718)
7. Chomczynski P, and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987;162:156-159. (Pubitemid 17064313)
8. Choo AY, Broderick KE, Kim JJ, and Sardesai NY: DNAbased influenza vaccines: evaluating their potential to provide universal protection. IDrugs 2010;13:707-712.
9. Demicheli V, Rivetti D, Deeks JJ, and Jefferson TO: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2000;CD001269.
10. Ellebedy AH, and Webby RJ: Influenza vaccines. Vaccine 2009;27(Suppl 4):D65-D68.
11. Epstein SL, Tumpey TM, Misplon JA, et al.: DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002;8:796-801.
12. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, and Robinson HL: DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-11482. (Pubitemid 24008662)
13. Gothelf A, and Gehl J: Gene electrotransfer to skin; review of existing literature and clinical perspectives. Curr Gene Ther 2010;10:287-299.
14. Gruber WC: The role of live influenza vaccines in children. Vaccine 2002;20(Suppl 2):S66-S73. (Pubitemid 34756350)
15. Henke A, Launhardt H, Klement K, Stelzner A, Zell R, and Munder T: Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva. J Virol 2000;74:4284-4290. (Pubitemid 30214436)
16. Henke A, Rohland N, Zell R, and Wutzler P: Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Intervirology 2006;49:249-252. (Pubitemid 43742511)
17. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, and Demicheli V: Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165-1174. (Pubitemid 41393594)
18. Jegerlehner A, Schmitz N, Storni T, and Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004;172:5598-5605. (Pubitemid 38542062)
19. Jimenez GS, Planchon R, Wei Q, et al: Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccine 2007;3:157-164. (Pubitemid 47598172)
20. Johnson PA, Conway MA, Daly J, Nicolson C, Robertson J, and Mills KH: Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses. J Gen Virol 2000;81:1737-1745. (Pubitemid 30427079)
21. Jones S, Evans K, McElwaine-Johnn H, et al.: DNA vaccination protects against an influenza challenge in a doubleblind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009;27:2506-2512.
22. Khalifah AP, Hachem RR, Chakinala MM, et al.: Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004;170: 181-187. (Pubitemid 38925165)
23. Kim WI, Wu WH, Janke B, and Yoon KJ: Characterization of the humoral immune response of experimentally infected and vaccinated pigs to swine influenza viral proteins. Arch Virol 2006;151:23-36. (Pubitemid 41813767)
24. Kodihalli S, Kobasa DL, and Webster RG: Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000;18:2592-2599. (Pubitemid 30207044)
25. Krumbholz A, Sandhaus T, Gohlert A, et al.: Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol 2010;199:317-322.
26. Liu MA: Immunologic basis of vaccine vectors. Immunity 2010;33:504-515.
27. Liu MA, and Ulmer JB: Human clinical trials of plasmid DNA vaccines. Adv Genet 2005;55:25-40. (Pubitemid 43580697)
28. Misplon JA, Lo CY, Gabbard JD, Tompkins SM, and Epstein SL: Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010;28:5817-5827.
29. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, and Haynes JR: Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995;13:1427-1430.
30. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
31. Qiu M, Fang F, Chen Y, Wang H, et al.: Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun 2006;343: 1124-1131.
32. Schmidtke M, Zell R, Bauer K, Krumbholz A, Schrader C, Suess J, and Wutzler P: Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 2006;49:286-293.
33. Smith LR, Wloch MK, Ye M, et al.: Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010;28:2565-2572.
34. Staud R, and Ramos LG: Influenza A-associated bronchiolitis obliterans organizing pneumonia mimicking Wegener's granulomatosis. Rheumatol Int 2001;20:125-128. (Pubitemid 32250125)
35. Stohr K: Influenza-WHO cares. Lancet Infect Dis 2002;2: 517.
36. Taubenberger JK, and Morens DM: Influenza: the once and future pandemic. Public Health Rep 2010;125(Suppl 3):16-26.
37. Ulmer JB: Influenza DNA vaccines. Vaccine 2002;20(Suppl 2):S74-S76. (Pubitemid 34756351)
38. Ulmer JB, Deck RR, DeWitt CM, Friedman A, Donnelly JJ, and Liu MA: Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 1994;12:1541-1544. (Pubitemid 24360571)
39. Ulmer JB, Donnelly JJ, Parker SE, et al.:. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749. (Pubitemid 23114660)
40. Vilchez RA, Dauber J, and Kusne S: Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection-myth or reality? Am J Transplant 2003;3:245-249. (Pubitemid 36407040)
41. Webster RG: Influenza virus: transmission between species and relevance to emergence of the next human pandemic. Arch Virol Suppl 1997;13:105-113. (Pubitemid 127502136)
42. Webster RG, Bean WJ, Gorman OT, Chambers TM, and Kawaoka Y: Evolution and ecology of influenza A viruses. Microbiol Rev 1992;56:152-179.
43. Webster RG, Fynan EF, Santoro JC, and Robinson H: Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 1994;12:1495-1498. (Pubitemid 24360561)
44. Xie H, Liu T, Chen H, Huang X, and Ye Z: Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid. Vaccine 2007;25: 7649-7655. (Pubitemid 47554469)
45. Zhang W, Li W, Li Y, et al.: Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes. J Med Microbiol 2009;58:845-854.
46. Zhirnov OP, Isaeva EI, Konakova TE, et al.: Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza Other Respir Viruses 2007;1:71-79.